Global Landscape and Temporal Evolution of Left Atrial Appendage Occlusion and Closure Research in Atrial Fibrillation (2006–2026): A 20-Year Bibliometric Analysis
Downloads
This study aimed to map publication trends, leading contributors, international collaboration patterns, and evolving research themes in left atrial appendage occlusion (LAAO), also referred to as left atrial appendage closure (LAAC), for patients with atrial fibrillation between 2006 and the 2026 literature search period.A bibliometric analysis was conducted using publications indexed in PubMed. An initial 3,684 records were identified and subsequently screened using predefined filters for publication date, language, document type, and preprint status, resulting in a final dataset of 833 publications from 230 publication sources. Bibliometrix, through its Biblioshiny interface, and VOSviewer were employed to analyze bibliometric indicators, research productivity, collaboration networks, and thematic developments.The final dataset comprised 833 publications involving 4,212 unique authors, with a reported annual publication growth rate of 21.42%. Research output and collaboration networks were predominantly concentrated in North America, Europe, and selected Asian countries. Thematic mapping indicated a shift from early investigations of procedural feasibility and safety toward imaging-guided interventions, device optimization, and postprocedural antithrombotic management. Publication data for 2026 represented the records available at the time of the literature search rather than a complete calendar-year assessment. The findings demonstrated substantial growth and increasing thematic diversity in LAAO/LAAC research over the study period. However, because the analysis was restricted to PubMed-indexed publications meeting specific eligibility criteria, the results reflected the characteristics of the selected bibliographic dataset rather than the entire global research landscape. Furthermore, bibliometric indicators and thematic networks did not establish the clinical effectiveness, comparative safety, or methodological quality of individual interventions or studies.
Blackshear, J. L., & Odell, J. A. (1996). Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. The Annals of Thoracic Surgery, 61(2), 755–759.
Boersma, L. V., Ince, H., Kische, S., et al. (2017). Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2017.05.038
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), 1139–1151.
Della Rocca, D. G., Magnocavallo, M., Di Biase, L., et al. (2021). Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC: Cardiovascular Interventions, 14, 2353–2364. https://doi.org/10.1016/j.jcin.2021.07.031
Donthu, N., Kumar, S., Mukherjee, D., Pandey, N., & Lim, W. M. (2021). How to conduct a bibliometric analysis: An overview and guidelines. Journal of Business Research, 133, 285–296.
Dukkipati, S. R., Kar, S., Holmes, D. R., et al. (2018). Device-related thrombus after left atrial appendage closure: Incidence, predictors, and outcomes. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.118.035090
Freeman, J. V., Higgins, A. Y., Wang, Y., et al. (2020). Trends in practice patterns and outcomes of percutaneous left atrial appendage occlusion with the WATCHMAN device in the United States. Journal of the American College of Cardiology, 75(13), 1503–1518.
Galea, R., De Marco, F., Meneveau, N., et al. (2022). Amulet or Watchman device for percutaneous left atrial appendage closure: Primary results of the SWISS-APERO randomized clinical trial. Circulation, 145(10), 724–738. https://doi.org/10.1161/CIRCULATIONAHA.121.057859
Gladstone, D. J., Lindsay, M. P., Douketis, J., Smith, E. E., Dowlatshahi, D., Wein, T., Bourgoin, A., Cox, J., Falconer, J. B., & Graham, B. R. (2022). Canadian stroke best practice recommendations: secondary prevention of stroke update 2020. Canadian Journal of Neurological Sciences, 49(3), 315–337.
Glikson, M., Wolff, R., Hindricks, G., et al. (2020). EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – An update. Europace, 22(2), 184.
Hindricks, G., Potpara, T., Dagres, N., et al. (2021). 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal, 42(5), 373–498.
Holmes, D. R., Reddy, V. Y., Turi, Z. G., et al. (2009). Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. The Lancet, 374(9689), 534–542.
Holmes, D. R., Jr., Kar, S., Price, M. J., et al. (2014). Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Journal of the American College of Cardiology, 64(1), 1–12.
Joglar, J. A., Chung, M. K., Armbruster, A. L., et al. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149(1), e1–e156.
Kar, S., Doshi, S. K., Sadhu, A., et al. (2021). Primary outcome evaluation of a next-generation left atrial appendage closure device: Results from the PINNACLE FLX trial. Circulation, 143(18). https://doi.org/10.1161/CIRCULATIONAHA.120.050117
Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century. Circulation Research, 127(1), 4–20.
Lakkireddy, D., Thaler, D., Ellis, C. R., et al. (2021). Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation, 144(19), 1543–1552.
Osmancik, P., Herman, D., Neuzil, P., et al. (2020). Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology, 75(25), 3122–3135.
Osmancik, P., Herman, D., Neuzil, P., et al. (2022). 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. Journal of the American College of Cardiology, 79(1), 1–14.
Reddy, V. Y., Doshi, S. K., Kar, S., et al. (2017). 5-year outcomes after left atrial appendage closure: From the PREVAIL and PROTECT AF trials. Journal of the American College of Cardiology, 70(24), 2964–2975.
Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., et al. (2013). Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). Journal of the American College of Cardiology, 61(25), 2551–2556.
Ruff, C. T., Giugliano, R. P., Braunwald, E., et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet, 383(9921), 955–962.
Whitlock, R. P., Belley-Cote, E. P., Paparella, D., et al. (2021). Left atrial appendage occlusion during cardiac surgery to prevent stroke. New England Journal of Medicine, 384(22), 2081–2091.
Copyright (c) 2026 Alan Dharmasaputra, Arga Setyo Adji, Ragil Nur Rosyadi, Intan Komalasari, Benny Jovie
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
